The empagliflozin/linagliptin combination is considered as a promising adjunct treatment option for patients with inadequate glycemic control on metformin. This combination therapy modestly reduces body weight and blood pressure without significant safety issues. 1 Boehringer Ingelheim India and Docplexus have organized a webinar on 31 st October 2020 from 03:00 PM IST onwards. In this webinar, Prof. Mark E Cooper will elucidate on the Expanding Treatment Options for Patients with Type 2 Diabetes: The Role of Empagliflozin+Linagliptin combination . We invite you to share your questions which will be answered by the expert at the end of the session.
Reference Tan X et.al., InAnnales d'endocrinologie 2016 Oct 1 (Vol. 77, No. 5, pp. 557-562). Elsevier Masson.
